<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PRF</journal-id>
<journal-id journal-id-type="hwp">spprf</journal-id>
<journal-id journal-id-type="nlm-ta">Perfusion</journal-id>
<journal-title>Perfusion</journal-title>
<issn pub-type="ppub">0267-6591</issn>
<issn pub-type="epub">1477-111X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0267659111424634</article-id>
<article-id pub-id-type="publisher-id">10.1177_0267659111424634</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Long-term use of the CentriMag<sup>®</sup> Ventricular Assist System as a right ventricular assist device: a case report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Griffith</surname><given-names>KE</given-names></name>
<xref ref-type="aff" rid="aff1-0267659111424634">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jenkins</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff1-0267659111424634">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Stulak</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff2-0267659111424634">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Paugh</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff1-0267659111424634">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pagani</surname><given-names>FD</given-names></name>
<xref ref-type="aff" rid="aff3-0267659111424634">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0267659111424634"><label>1</label>Cardiovascular Center Perfusion Services, University of Michigan Hospitals, Ann Arbor, MI, USA</aff>
<aff id="aff2-0267659111424634"><label>2</label>Cardiac Surgery, University of Michigan Hospitals, Ann Arbor, MI, USA</aff>
<aff id="aff3-0267659111424634"><label>3</label>Heart Transplant Program and Center for Circulatory Support, University of Michigan Hospitals, Ann Arbor, MI, USA</aff>
<author-notes>
<corresp id="corresp1-0267659111424634">Kevin E. Griffith University of Michigan Hospitals Cardiovascular Center Perfusion Services 4157 Cardiovascular Center 1500 E. Medical Center Drive Ann Arbor, MI 48109-5863 USA Email: <email>kegriff@med.umich.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>1</issue>
<fpage>65</fpage>
<lpage>70</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Right ventricular failure (RVF) following implantation of a left ventricular assist system (LVAS) is associated with high morbidity and mortality.<sup><xref ref-type="bibr" rid="bibr1-0267659111424634">1</xref>-<xref ref-type="bibr" rid="bibr4-0267659111424634">4</xref></sup> Numerous centers have reported short-term use of the CentriMag<bold><sup>®</sup></bold> Ventricular Assist System (CVAS) (Levitronix LLC, Waltham, MA) for treatment of cardiogenic shock, decompensated heart failure and right ventricular failure (RVF) following LVAS implantation.<sup><xref ref-type="bibr" rid="bibr5-0267659111424634">5</xref>-<xref ref-type="bibr" rid="bibr9-0267659111424634">9</xref></sup> The present report reviews the clinical course of a patient requiring long-term right ventricular support utilizing the CVAS, following a HeartMate<bold><sup>®</sup></bold> II LVAS (Thoratec Corp. Pleasanton, CA) implantation. Elevated cytotoxic antibody levels complicated the patient’s treatment plan by precluding orthotropic heart transplantation. The CVAS operated for 304 days without mechanical difficulty until replaced with the HeartWare<bold><sup>®</sup></bold> Ventricular Assist System (HeartWare Inc. Miramar, FL).</p>
</abstract>
<kwd-group>
<kwd>CentriMag<bold><sup>®</sup></bold> ventricular assist system</kwd>
<kwd>circulatory support</kwd>
<kwd>right ventricular failure</kwd>
<kwd>centrifugal pump</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0267659111424634" sec-type="intro">
<title>Introduction</title>
<p>Mechanical circulatory support has become an accepted modality in the treatment of end-stage heart failure. Currently, left ventricular assist systems (LVAS) are used as a temporary support in patients expected to recover, as a bridge to heart transplantation patients, and as an alternative to transplantation in patients who do not meet transplant criteria. Optimal LVAS performance depends on the patient’s native right ventricular (RV) function. RV failure (RVF) leads to poor LVAS filling and low pump output, increasing morbidity and mortality.<sup><xref ref-type="bibr" rid="bibr1-0267659111424634">1</xref>,<xref ref-type="bibr" rid="bibr3-0267659111424634">3</xref>,<xref ref-type="bibr" rid="bibr4-0267659111424634">4</xref></sup> Expanding clinical experience and improved patient management techniques have aided in decreasing the incidence of RVF following LVAS implantation to approximately 20 percent. Severe RVF, requiring the use of a right ventricular assist system (RVAS), occurs in less than 10 percent of patients receiving an LVAS implant. Reported mortality rates for this group are as high as 70 percent.<sup><xref ref-type="bibr" rid="bibr1-0267659111424634">1</xref>,<xref ref-type="bibr" rid="bibr2-0267659111424634">2</xref>,<xref ref-type="bibr" rid="bibr4-0267659111424634">4</xref></sup></p>
<p>A number of centers have reported short-term use of the CentriMag<bold><sup>®</sup></bold> ventricular assist system (CVAS) for treatment of cardiogenic shock, decompensated heart failure, and RVF following LVAS implantation.<sup><xref ref-type="bibr" rid="bibr5-0267659111424634">5</xref>-<xref ref-type="bibr" rid="bibr9-0267659111424634">9</xref></sup> The CentriMag<bold><sup>®</sup></bold> system consists of a paracorporeal magnetically levitated centrifugal blood pump designed for temporary use as an RVAS, LVAS, or BiVAS. (<xref ref-type="fig" rid="fig1-0267659111424634">Figure 1</xref>) A remote motor unit generates the magnetic force to levitate the blood pump impeller and also produces torque for impeller rotation. Magnetic levitation of the blood pump impeller minimizes wear, heat generation, and thrombus formation inside the device. The pump and motor unit are controlled from a console that incorporates a transonic flow probe for accurate blood flow determination and a one-hour rechargeable battery for mobile operation.</p>
<fig id="fig1-0267659111424634" position="float">
<label>Figure 1.</label>
<caption>
<p>CentriMag<bold><sup>®</sup></bold> Ventricular Assist System</p>
<p>Reproduced with permission Levitronix LLC, Waltham, MA</p>
</caption>
<graphic xlink:href="10.1177_0267659111424634-fig1.tif"/>
</fig>
<p>The current report reviews the clinical course of a patient supported for 304 days on the CVAS as an RVAS for persistent RVF and elevated pulmonary vascular resistance following HeartMate<bold><sup>®</sup></bold> II LVAS implantation. The patient’s care plan was further complicated by elevated cytotoxic antibody levels. precluding orthotropic heart transplant. The CVAS was subsequently replaced with the implantable HeartWare<bold><sup>®</sup></bold>ventricular assist system.</p>
</sec>
<sec id="section2-0267659111424634" sec-type="cases">
<title>Case Report</title>
<p>A 59-year-old female patient was transferred from an affiliate community hospital with a two-week history of shortness of breath, cough, orthopnea, and fatigue. She had previously been diagnosed, at age 30, with non-ischemic, dilated cardiomyopathy and hypertension. A previous coronary angiogram demonstrated the absence of coronary artery disease. Her heart failure symptoms had progressed to the point of requiring hospitalization annually over the past several years. The initial physical exam revealed a well-nourished, 61 inch (155 cm), 113 lb (51 kg) female with a body surface area (BSA) of 1.48 m<sup>2</sup> and a body mass index (BMI) of 21.35 kg/m<sup>2</sup>. She was normothermic, with mild tachycardia, and exhibited mild crackles at the lung bases. Her baseline blood and urine analyses did not reveal any abnormal findings. Heart catheterization revealed severe tricuspid and mitral valve regurgitation, biventricular pressure overload, 2.03 L/m cardiac output (Fick), 1.4 L/min/m<sup>2</sup> cardiac index, 136.76 cc-mmHg/m<sup>2</sup>/beat right ventricular stroke work index, and 56/38 mmHg pulmonary artery pressure. (<xref ref-type="table" rid="table1-0267659111424634">Table 1</xref>) Transesophageal echocardiogram exhibited severe global left ventricular systolic dysfunction, moderate right ventricular dysfunction, mild right and moderate left ventricular enlargement, severe mitral valve regurgitation, dilated mitral annulus, moderate tricuspid valve regurgitation, moderate pulmonary hypertension, and 10% ejection fraction. Intra-aortic balloon pump counterpulsation was initiated at this time. Over the next several days, the patient’s heart function continued to deteriorate and a decision was made for a HeartMate<bold><sup>®</sup></bold> II LVAS implantation. (<xref ref-type="table" rid="table1-0267659111424634">Table 1</xref>) Simultaneous temporary CentriMag<bold><sup>®</sup></bold> right ventricular assist device placement was planned due to the presence of multiple risk factors for RVF.<sup><xref ref-type="bibr" rid="bibr13-0267659111424634">13</xref>,<xref ref-type="bibr" rid="bibr14-0267659111424634">14</xref></sup></p>
<table-wrap id="table1-0267659111424634" position="float">
<label>Table 1.</label>
<caption>
<p>Catheterization and Laboratory Values</p>
</caption>
<graphic alternate-form-of="table1-0267659111424634" xlink:href="10.1177_0267659111424634-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left" colspan="3">Catheterization/Laboratory Values</th>
</tr>
<tr>
<th/>
<th align="left">Admission</th>
<th align="left">Pre LVAS</th>
<th align="left">Post CVAS/HM II</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR bpm</td>
<td>86</td>
<td>144</td>
<td>119</td>
</tr>
<tr>
<td>B/P mmHg</td>
<td>92/72</td>
<td>107/80</td>
<td>123/95</td>
</tr>
<tr>
<td>CVP mmHg</td>
<td>17</td>
<td>30</td>
<td>8</td>
</tr>
<tr>
<td>RV mmHg</td>
<td>49/13</td>
<td>50/15</td>
<td>52/6</td>
</tr>
<tr>
<td>PCWP mmHg</td>
<td>25</td>
<td>28</td>
<td>11</td>
</tr>
<tr>
<td>PA mmHg</td>
<td>53/27</td>
<td>56/38</td>
<td>50/29</td>
</tr>
<tr>
<td>CO Fick lpm</td>
<td>2.05</td>
<td>2.03</td>
<td>4.44</td>
</tr>
<tr>
<td>CI Fick lpm/m<sup>2</sup></td>
<td>1.41</td>
<td>1.40</td>
<td>3.07</td>
</tr>
<tr>
<td>PVR dynes…</td>
<td>468.93</td>
<td>552.04</td>
<td>432.23</td>
</tr>
<tr>
<td>PVR woods units</td>
<td>5.86</td>
<td>6.9</td>
<td>5.4</td>
</tr>
<tr>
<td>SVR dynes…</td>
<td>2380.48</td>
<td>2405.3</td>
<td>1866.6</td>
</tr>
<tr>
<td>SVR woods units</td>
<td>30.13</td>
<td>30.07</td>
<td>23.62</td>
</tr>
<tr>
<td>RVSWI cc-mmHg/m<sup>2</sup>/beat</td>
<td>325.74</td>
<td>136.76</td>
<td/>
</tr>
<tr>
<td>CVP/PCWP Ratio</td>
<td>0.68</td>
<td>1.07</td>
<td>0.72</td>
</tr>
<tr>
<td>Hct percent</td>
<td>34</td>
<td>29.1</td>
<td>26.7</td>
</tr>
<tr>
<td>WBC × 10<sup>3</sup>/ml</td>
<td>5.2</td>
<td>10.9</td>
<td>7.0</td>
</tr>
<tr>
<td>BUN</td>
<td>20</td>
<td>33</td>
<td>14</td>
</tr>
<tr>
<td>Creatinine</td>
<td>1.0</td>
<td>1.1</td>
<td>0.7</td>
</tr>
<tr>
<td>AST</td>
<td>113</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0267659111424634">
<p><italic>HR</italic>: heart rate; <italic>B/P</italic>: blood pressure; <italic>CVP</italic>: central venous pressure; <italic>RV</italic>: right ventricular pressure; <italic>PCWP</italic>: pulmonary capillary wedge pressure; <italic>PA</italic>: pulmonary artery pressure; <italic>CO</italic>: cardiac output; <italic>CI</italic>: cardiac index; <italic>PVR</italic>: pulmonary vascular resistance; <italic>SVR</italic>: systemic vascular resistance; <italic>RVSWI</italic>: right ventricular stroke work index; <italic>CVP/PCWP</italic>: central venous pressure pulmonary capillary wedge pressure ratio; <italic>Hct</italic>: hematocrit; <italic>WBC</italic>: white blood count; <italic>BUN</italic>: blood urea nitrogen; <italic>AST</italic>: aspartate aminotransferase</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The HeartMate<bold><sup>®</sup></bold> II device was implanted in the manner previously described, using cardiopulmonary bypass.<sup><xref ref-type="bibr" rid="bibr10-0267659111424634">10</xref></sup> An Abiomed<sup>®</sup> 32 Fr. venous cannula (Abiomed Inc., Danvers, MA) was placed in the right atrium, and an Abiomed 10 mm arterial cannula with a Hemashield™ graft was anastomosed to the pulmonary artery. The cannulae were externalized and then connected to the CentriMag<bold><sup>®</sup></bold> blood pump inflow and outflow orifices via four foot lengths of 3/8 inch polyvinyl chloride tubing (Medtronic Corp., Minneapolis, MN). (<xref ref-type="fig" rid="fig2-0267659111424634">Figure 2</xref>) The patient was weaned from cardiopulmonary bypass with the following initial device settings: LVAS speed 8800 rpm, power 4.9 watts, pulsatility index 5.2, flow 3.9 L/m, CVAS speed 2300 rpm and flow 3.5 L/m. The patient’s vital signs were: arterial blood pressure 133/87 mmHg, central venous pressure 10 mmHg, heart rate 99 beats per minute (bpm), and bladder temperature 37°C. The patient was maintained on vasopressin 3.0 units/hr, dobutamine 10 μg/kg/min, and 80 parts per million (ppm) inhaled nitric oxide. During the intraoperative and postoperative periods, the patient received 7 units of packed red blood cells (RBC), 5 units of pooled platelets, and 13 units of fresh frozen plasma (FFP).</p>
<fig id="fig2-0267659111424634" position="float">
<label>Figure 2.</label>
<caption>
<p>CentriMag<bold><sup>®</sup></bold> RVAS and HeartMate<bold><sup>®</sup></bold> II LVAS</p>
<p>Reproduced with permission Levitronix LLC, Waltham, MA</p>
</caption>
<graphic xlink:href="10.1177_0267659111424634-fig2.tif"/>
</fig>
<p>Efforts to wean the CVAS were not successful and the patient returned to the operating room on the second post implant day (PID) for mediastinal exploration and delayed sternal closure. The CVAS tubing and connectors were changed at this time due to the presence of thrombus at the tubing connector junctions. The nitric oxide was discontinued and the patient weaned from mechanical ventilation on PID 4. She was out of bed on PID 7 and exercise tolerance increased to 45 minute walks by PID 10. Postoperative complications consisted of a large left pleural effusion, requiring drainage by thoracentesis on PID 65 and a segmental pulmonary embolism (PE) of the right main and lobar pulmonary arteries on PID 74.</p>
<p>Over the first few postoperative weeks, the patient’s pulmonary artery pressure remained elevated at 50/29 mmHg, with pulmonary vascular resistance at 432.23 dynes-second-cm<sup>-5</sup> (5.4 Wood units). Several attempts at CVAS weaning were unsuccessful and the patient was subsequently listed status 1A for heart transplantation. (<xref ref-type="table" rid="table1-0267659111424634">Table 1</xref>) A transplant work-up revealed the presence of multiple alloantibodies, with a high panel of reactive antibody (PRA). Over the course of the next nine months, strategies to abrogate antibody production consisted of four plasmapheresis infusions, intravenous immunoglobulin (IVIG) administration and bortezomib (Velcade<bold><sup>®</sup></bold>) administration, a reversible inhibitor of proteolytic activity of the intracellular proteasome complex. Repeated efforts to reduce antibody levels and to wean the CVAS were unsuccessful.</p>
<p>On PID 304, the CVAS was replaced with the HeartWare<bold><sup>®</sup></bold> ventricular assist system (HVAS). The patient returned to the operating room the following day for partial sternectomy and bilateral pectoralis muscle flaps to facilitate coverage of the implanted HVAS. The patient’s postoperative course was uneventful and discharge occurred 27 days later.</p>
</sec>
<sec id="section3-0267659111424634">
<title>Anticoagulation</title>
<p>The anticoagulation regimen consisted of 150 mg dipyridamole three times per day and 325 mg aspirin, beginning on PID 1. Argatroban was added on PID 6 at 0.1 μg/kg/min, with a target partial thromboplastin time (PTT) of 35-40 seconds. On PID 8, the argatroban dose was increased to 0.2 μg/kg/min, with a target PTT of 40-45 seconds. Over the course of the next ten days, the argatroban dose was increased to 2.4 μg/kg/min and the PTT target was raised to 55-60 seconds due to thrombus deposition within the CVAS circuit. The entire CVAS circuit was changed at this time, with the exception of the implanted cannulae. In response to a diagnosis of PE on PID 74, the target PTT was raised to 60-70 seconds. (<xref ref-type="fig" rid="fig3-0267659111424634">Figure 3</xref> &amp; <xref ref-type="fig" rid="fig4-0267659111424634">4</xref>)</p>
<fig id="fig3-0267659111424634" position="float">
<label>Figure 3.</label>
<caption>
<p>Partial Thromboplastin Time: seconds</p>
</caption>
<graphic xlink:href="10.1177_0267659111424634-fig3.tif"/>
</fig>
<fig id="fig4-0267659111424634" position="float">
<label>Figure 4.</label>
<caption>
<p>International Normalized Ratio</p>
</caption>
<graphic xlink:href="10.1177_0267659111424634-fig4.tif"/>
</fig>
</sec>
<sec id="section4-0267659111424634" sec-type="discussion">
<title>Discussion</title>
<p>RVF is a significant problem following LVAS implantation. Severe RVF may require the use of a right ventricular assist device to maintain adequate blood flow to the LVAS. In the largest multicenter study to date which analyzes 484 patients implanted with the HeartMate<sup>®</sup> II, Kormos et al. report the incidence of RVF at 20% and severe RVF requiring RVAS at 6%.<sup><xref ref-type="bibr" rid="bibr1-0267659111424634">1</xref></sup> In this study, mortality for patients with LVAS implants requiring RVAS was 41%.<sup><xref ref-type="bibr" rid="bibr1-0267659111424634">1</xref></sup> Lack of an implantable device specifically designed as an RVAS is a contributing factor to the high mortality of this group.</p>
<p>High preoperative white blood cell (WBC) count, blood urea nitrogen (BUN) value, and preoperative ventilatory support, increased central venous pressure (CVP), central venous pressure pulmonary capillary wedge pressure ratio (CVP/PCWP) and decreased right ventricular stroke work index (RVSWI), have been found to be significant univariate predictors of RVF following LVAS implantation.<sup><xref ref-type="bibr" rid="bibr1-0267659111424634">1</xref></sup> A CVP/PCWP ratio of greater than 0.63 has been found to be an independent multivariate risk factor for RVF.<sup><xref ref-type="bibr" rid="bibr1-0267659111424634">1</xref></sup> The current patient presented with a number of the risk factors for RVF, justifying placement of biventricular support.<sup><xref ref-type="bibr" rid="bibr6-0267659111424634">6</xref></sup> Development of severe persistent RVF, regardless of appropriate management and prevention, remains difficult to predict.</p>
<p>Several paracorporeal short-term systems exist that can be used as temporary RVAS. These short-term systems are pressed into longer service in the face of persistent severe RVF in the attempt to bridge patients to heart transplantation. The major problems associated with pushing these temporary systems for long-term use are mechanical failure and thrombus deposition in the circuit.</p>
<p>Cleared for use in Europe in 2002 and the United States of America in 2003, the CVAS is now available in over 40 countries around the world. The CVAS has been employed as a RVAS, a LVAS, a BiVAS, and a blood pump for extracorporeal membrane oxygenation (ECMO).<sup><xref ref-type="bibr" rid="bibr7-0267659111424634">7</xref>-<xref ref-type="bibr" rid="bibr11-0267659111424634">11</xref></sup> The Food and Drug Administration has also specifically cleared the use of the CVAS for up to 30 days as an RVAS in the U.S.A. Accordingly, scheduled replacement of the CVAS every 2 to 6 weeks has been variously instituted to obviate mechanical failure; however, two reports have attested to the greater longevity of the device.<sup><xref ref-type="bibr" rid="bibr5-0267659111424634">5</xref>,<xref ref-type="bibr" rid="bibr8-0267659111424634">8</xref></sup></p>
<p>This patient had one pump exchange on PID 18 due to identification of thrombus deposits within the tubing, connectors, and implanted cannulae. The inflow and outflow implanted cannulae, however, were not exchanged due to the significant surgical risk. Surgical intervention to replace the cannulae could also have had a negative impact on efforts to decrease the patient’s elevated cytotoxic antibody levels. Examination of the pump revealed no deposits or structural degeneration. Nevertheless, since thrombogenesis could occur anywhere within the CVAS, it was resolved exchanging only part of the circuit did not significantly reduce the risk of embolism. Therefore, the CVAS circuit was not altered for the remaining 286 days of patient support. System components were inspected daily and a care plan was implemented to manage the patient in the event of mechanical failure of the CVAS. Thrombus, which probably originated in the CVAS circuit, resulted in pulmonary embolism on PID 74. The pulmonary embolism resolved by increasing the argatroban dose to increase the PTT to 60-70 seconds.</p>
<p>While not endorsed by the manufacturer, the length of this patient’s support period greatly increased our experience with the CentriMag<bold><sup>®</sup></bold> system. The CVAS console and drive motor operated without incident for the entire 304 days of support. One CentriMag<bold><sup>®</sup></bold> blood pump operated without interruption for 286 days. Postoperational analysis revealed the absence of pump deposits and wear. The CVAS battery system allowed adequate portable operation of the system to permit the patient to move freely around the hospital.</p>
<p>Severe hemolysis can be a serious complication associated with LVAS use and can be compounded during bilateral mechanical circulatory support. Hemolysis is the result of shear stress, flow acceleration, and interaction with artificial surfaces and leads to anemia and elevated serum levels of free hemoglobin and lactate dehydrogenase (LDH). Following blood transfusions during this patient’s initial device implant, hemoglobin and hematocrit levels remained stable until PID 40 when two units of RBC were required during a plasmapheresis treatment. No additional RBC transfusions were required for the remaining 264 days of CVAS support. (<xref ref-type="fig" rid="fig5-0267659111424634">Figure 5</xref> &amp; <xref ref-type="fig" rid="fig6-0267659111424634">6</xref>)</p>
<fig id="fig5-0267659111424634" position="float">
<label>Figure 5.</label>
<caption>
<p>Hemoglobin: grams/deciliter</p>
</caption>
<graphic xlink:href="10.1177_0267659111424634-fig5.tif"/>
</fig>
<fig id="fig6-0267659111424634" position="float">
<label>Figure 6.</label>
<caption>
<p>Hematocrit: percent</p>
</caption>
<graphic xlink:href="10.1177_0267659111424634-fig6.tif"/>
</fig>
<p>Red blood cell destruction leading to moderate elevation of serum hemoglobin and LDH has been reported with the use of the HeartMate II LVAS.<sup><xref ref-type="bibr" rid="bibr15-0267659111424634">15</xref>,<xref ref-type="bibr" rid="bibr16-0267659111424634">16</xref></sup> This patient, while being supported on both the HeartMate II LVAS and CentriMag<bold><sup>®</sup></bold> VAS, did not have serum hemoglobin or LDH levels significantly different from those previously reported for the HeartMate II alone. (<xref ref-type="fig" rid="fig7-0267659111424634">Figure 7</xref> &amp; <xref ref-type="fig" rid="fig8-0267659111424634">8</xref>) Therefore, the CVAS did not compound this patient’s level of hemolysis, as might be expected during long-term biventricular support.</p>
<fig id="fig7-0267659111424634" position="float">
<label>Figure 7.</label>
<caption>
<p>Serum Free Hemoglobin: milligrams/deciliter</p>
</caption>
<graphic xlink:href="10.1177_0267659111424634-fig7.tif"/>
</fig>
<fig id="fig8-0267659111424634" position="float">
<label>Figure 8.</label>
<caption>
<p>Lactate Dehydrogenase: international units/liter</p>
</caption>
<graphic xlink:href="10.1177_0267659111424634-fig8.tif"/>
</fig>
<p>Efforts at reducing the patient’s cytotoxic antibody levels were not successful, precluding orthotropic heart transplantation. (<xref ref-type="fig" rid="fig9-0267659111424634">Figure 9</xref>) The focus of the care team shifted to providing the patient with an implantable, portable RVAS that would permit discharge from the hospital. Since no electric implantable RVAS is available, compassionate use approval was obtained to modify and implant the HeartWare<bold><sup>®</sup></bold> LVAS as a RVAS. The total hospital length of stay was 348 days, all of which were spent in the intensive care unit. At the time of writing, the patient has been functioning at home for five months without difficulty.</p>
<fig id="fig9-0267659111424634" position="float">
<label>Figure 9.</label>
<caption>
<p>Panel Reactive Antibody: percent</p>
</caption>
<graphic xlink:href="10.1177_0267659111424634-fig9.tif"/>
</fig>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="presented-at">
<p>Presented at the 32nd Annual Seminar of The American Academy of Cardiovascular Perfusion, Reno, Nevada, 27-30, January, 2011.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<p>None Declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0267659111424634">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kormos</surname><given-names>R</given-names></name>
<name><surname>Teuteberg</surname><given-names>J</given-names></name>
<name><surname>Pagani</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Right ventricular failure in patients with the HeartMate<sup>®</sup> II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes</article-title>. <source>J Thorac Cardiovasc Surg</source> <year>2010</year>; <volume>139</volume>: <fpage>1316</fpage>–<lpage>1324</lpage>.</citation>
</ref>
<ref id="bibr2-0267659111424634">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drakos</surname><given-names>S</given-names></name>
<name><surname>Janicki</surname><given-names>L</given-names></name>
<name><surname>Horne</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Risk factors predictive of right ventricular failure after left ventricular assist device implantation</article-title>. <source>Am J Cardiol</source> <year>2010</year>; <volume>105</volume>: <fpage>1030</fpage>–<lpage>1035</lpage>.</citation>
</ref>
<ref id="bibr3-0267659111424634">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dang</surname><given-names>N</given-names></name>
<name><surname>Topkara</surname><given-names>V</given-names></name>
<name><surname>Mercando</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure</article-title>. <source>J Heart Lung Transplant</source> <year>2006</year>; <volume>25</volume>: <fpage>1</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr4-0267659111424634">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zahr</surname><given-names>F</given-names></name>
<name><surname>Ootaki</surname><given-names>Y</given-names></name>
<name><surname>Starling</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Preoperative risk factors for mortality after biventricular assist device implantation</article-title>. <source>J Cardiac Fail</source> <year>2008</year>; <volume>14</volume>: <fpage>844</fpage>–<lpage>849</lpage>.</citation>
</ref>
<ref id="bibr5-0267659111424634">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haj-Yahia</surname><given-names>S</given-names></name>
<name><surname>Birks</surname><given-names>E</given-names></name>
<name><surname>Amrani</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Bridging patients after salvage from bridge to decision directly to transplant by means of prolonged support with the CentriMag<sup>®</sup> short-term centrifugal pump</article-title>. <source>J Thoracic Cardiovascular Surgery</source> <year>2009</year>; <volume>138</volume>: <fpage>227</fpage>–<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr6-0267659111424634">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Loforte</surname><given-names>A</given-names></name>
<name><surname>Montalto</surname><given-names>A</given-names></name>
<name><surname>Monica</surname><given-names>P</given-names></name>
<name><surname>Musumeci</surname><given-names>F</given-names></name>
</person-group>. <article-title>Simultaneous temporary CentriMag<sup>®</sup> right ventricular assist device placement in HeartMate<sup>®</sup> II left ventricular assist system recipients at high risk of right ventricular failure</article-title>. <source>Interact CardioVasc ThoracSurg</source> <year>2010</year>; <volume>10</volume>: <fpage>847</fpage>–<lpage>850</lpage>.</citation>
</ref>
<ref id="bibr7-0267659111424634">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>John</surname><given-names>R</given-names></name>
<name><surname>Kamdar</surname><given-names>F</given-names></name>
<name><surname>Liao</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Improved survival and decreasing incidence of adverse events with the HeartMate<sup>®</sup> II left ventricular assist device as bridge-to-transplant therapy</article-title>. <source>Ann Thorac Surg</source> <year>2008</year>; <volume>86</volume>: <fpage>1227</fpage>–<lpage>1235</lpage>.</citation>
</ref>
<ref id="bibr8-0267659111424634">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shuhaiber</surname><given-names>J</given-names></name>
<name><surname>Jenkins</surname><given-names>D</given-names></name>
<name><surname>Berman</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>The Papworth experience with the Levitronix CentriMag<sup>®</sup> ventricular assist device</article-title>. <source>J Heart Lung Transplant</source> <year>2008</year>; <volume>27</volume>: <fpage>158</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr9-0267659111424634">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhama</surname><given-names>J</given-names></name>
<name><surname>Kormos</surname><given-names>R</given-names></name>
<name><surname>Toyoda</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Clinical experience using the Levitronix CentriMag<sup>®</sup> system for temporary right ventricular mechanical circulatory support</article-title>. <source>J Heart Lung Transplant</source> <year>2009</year>; <volume>28</volume>: <fpage>971</fpage>–<lpage>976</lpage>.</citation>
</ref>
<ref id="bibr10-0267659111424634">
<label>10.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Goldstein</surname><given-names>D</given-names></name>
<name><surname>Zucker</surname><given-names>M</given-names></name>
<name><surname>Pagani</surname><given-names>FD</given-names></name>
<etal/>
</person-group>. <article-title>Rotary ventricular assist devices</article-title>. In: <person-group person-group-type="editor">
<name><surname>Farzier</surname><given-names>OH</given-names></name>
<name><surname>Kirklin</surname><given-names>JK</given-names></name>
</person-group>, eds. <source>Mechanical circulatory support. ISHLT Monograph Series</source>. <volume>Vol. 1</volume> <publisher-loc>Oxford, England</publisher-loc>: <publisher-name>Elsevier</publisher-name> <year>2006</year>: <fpage>77</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr11-0267659111424634">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Robertis</surname><given-names>F</given-names></name>
<name><surname>Rogers</surname><given-names>P</given-names></name>
<name><surname>Amrani</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Bridge to decision using the Levitronix CentriMag<sup>®</sup> short-term ventricular assist device</article-title>. <source>J Heart Lung Transplant</source> <year>2008</year>; <volume>27</volume>: <fpage>474</fpage>–<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr12-0267659111424634">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griffith</surname><given-names>K</given-names></name>
<name><surname>Jenkins</surname><given-names>E</given-names></name>
<name><surname>Haft</surname><given-names>J</given-names></name>
</person-group>. <article-title>Treatment of massive pulmonary embolism utilizing a multidisciplinary approach: a case study</article-title>. <source>Perfusion</source> <year>2009</year>; <volume>24</volume>(<issue>3</issue>): <fpage>169</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr13-0267659111424634">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matthews</surname><given-names>J</given-names></name>
<name><surname>Koelling</surname><given-names>T</given-names></name>
<name><surname>Pagani</surname><given-names>F</given-names></name>
<name><surname>Aaronson</surname><given-names>K</given-names></name>
</person-group>. <article-title>The right ventricular failure risk score</article-title>. <source>J American College of Cardiology</source> <year>2008</year>; <volume>51</volume>(<issue>22</issue>): <fpage>2163</fpage>–<lpage>2172</lpage>.</citation>
</ref>
<ref id="bibr14-0267659111424634">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Romano</surname><given-names>M</given-names></name>
<name><surname>Cowger</surname><given-names>J</given-names></name>
<name><surname>Aaronson</surname><given-names>K</given-names></name>
<name><surname>Pagani</surname><given-names>F</given-names></name>
</person-group>, <article-title>Diagnosis and management of right-sided heart failure in subjects supported with left ventricular assist devices</article-title>. <source>Curr Treat Options Cardiovasc Med</source> <year>2010</year>; <volume>12</volume>: <fpage>420</fpage>–<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr15-0267659111424634">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heilmann</surname><given-names>C</given-names></name>
<name><surname>Geisen</surname><given-names>U</given-names></name>
<name><surname>Benk</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Haemolysis in patients with ventricular assist devices: major differences between systems</article-title>. <source>Eur J Cardiothorac Surg</source> <year>2009</year>; <volume>36</volume>: <fpage>580</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr16-0267659111424634">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Slaughter</surname><given-names>M</given-names></name>
<name><surname>Sobieski</surname><given-names>M</given-names></name>
<name><surname>Gallagher</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Fibrinolytic activation during long-term support with the HeartMate<sup>®</sup> II left ventricular assist device</article-title>. <source>ASAIO J</source> <year>2008</year>; <volume>54</volume>: <fpage>115</fpage>–<lpage>119</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>